Parkinson's disease (PD) is a growing global health problem that causes untold suffering for patients and their loved ones, and challenges health care systems. Motor symptoms are the classic features for which there are some effective interventions;however, non-motor symptoms, especially cognitive impairment, are very common, may precede motor symptoms, and do not respond well to existing therapies. Solutions will come only from research. The Pacific Northwest Udall Center (PANUC), one of ten NINDS-funded Morris K. Udall Centers of Excellence for Parkinson's Disease Research, is our response to this research imperative. The overall goal of PANUC is to develop the knowledge and tools of precision medicine for cognitive impairment in PD so that the right person gets the right prevention or treatment at the right time. Our innovative three cores and four projects focus on genetic risk for cognitive impairment in PD;development of new therapeutic targets based on molecular mechanisms or mechanisms of disease;detection of preclinical or early disease using novel brain imaging;and a proof-of-concept clinical trial for balance and gait problems, in part an expression of cognitive impairment. Each of our research goals is ranked among the highest priority recommendations of two recent NINDS Conferences: Parkinson's Disease 2014: Advancing Research, Improving Lives and Alzheimer's Disease-Related Dementias: Research Challenges and Opportunities 2013 (which included PD dementia). PANUC is committed to continuing our efforts to contribute to the prevention and treatment of cognitive impairment in PD through precision medicine.
The National Institutes of Health (NIH) estimates that over half a million people in the United States suffer from Parkinson's disease, causing untold suffering to patients as well as their caregivers and other loved ones. The physical, emotional, and societal costs of Parkinson's disease will increase over the coming decades as more of us live longer. Cognitive impairment is a common feature of Parkinson's disease that is disabling for patients and challenging to caregivers. Our center is focused on the clear imperative to find better tools for diagnosis and better ways to treat cognitive impairment in patients with Parkinson's disease.
|Flanagan, Margaret E; Cholerton, Brenna; Latimer, Caitlin S et al. (2018) TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. J Alzheimers Dis 66:1549-1558|
|Gray, Shelly L; Anderson, Melissa L; Hanlon, Joseph T et al. (2018) Exposure to Strong Anticholinergic Medications and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. J Alzheimers Dis 65:607-616|
|Moreno, Monica A; Or-Geva, Noga; Aftab, Blake T et al. (2018) Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurol Neuroimmunol Neuroinflamm 5:e466|
|Condello, Carlo; Lemmin, Thomas; Stöhr, Jan et al. (2018) Structural heterogeneity and intersubject variability of A? in familial and sporadic Alzheimer's disease. Proc Natl Acad Sci U S A 115:E782-E791|
|Locke, Timothy M; Soden, Marta E; Miller, Samara M et al. (2018) Dopamine D1 Receptor-Positive Neurons in the Lateral Nucleus of the Cerebellum Contribute to Cognitive Behavior. Biol Psychiatry 84:401-412|
|Cholerton, Brenna; Johnson, Catherine O; Fish, Brian et al. (2018) Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism Relat Disord 50:29-36|
|Blue, Elizabeth E; Bis, Joshua C; Dorschner, Michael O et al. (2018) Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. Dement Geriatr Cogn Disord 45:1-17|
|Houser, Madelyn C; Chang, Jianjun; Factor, Stewart A et al. (2018) Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease. Mov Disord 33:793-804|
|Wile, Daryl J; Agarwal, Pankaj A; Schulzer, Michael et al. (2017) Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol 16:351-359|
|Dublin, Sascha; Walker, Rod L; Gray, Shelly L et al. (2017) Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. J Alzheimers Dis 58:435-448|
Showing the most recent 10 out of 178 publications